Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Antithrombin III (AT3) in Infectious Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)/ Coronavirus Disease of 2019 (COVID-19)

NCT04899232 is registered in ClinicalTrials.gov with Enrique Ginzburg as lead sponsor.

NCT NCT04899232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04899232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Antithrombin III (AT3) in Infectious Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)/ Coronavirus Disease of 2019 (COVID-19)
Lead sponsor
Enrique Ginzburg
Phase
Phase 2
Overall status
Terminated
Start date
July 6, 2021
Completion date
March 31, 2022
Enrollment
52 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antithrombin iii deficiency, covid19